Renova Retin-A
Spotlight on adapalene in acne vulgaris.

Waugh J, Noble S, Scott LJ.

Adis International Inc, Yardley, PA 19067, USA. demail adis.com

Adapalene (Differin) is a retinoid agent indicated for the topical treatment of acne vulgaris. In clinical trials, 0.1% adapalene gel has proved to be effective in this indication and was as effective as 0.025% tretinoin gel, 0.1% tretinoin microsphere gel, 0.05% tretinoin cream and 0.1% tazarotene gel once every two days; however, the drug was less effective than once-daily 0.1% tazarotene gel. It can be used alone in mild acne or in combination with antimicrobials in inflammatory acne and has proved efficacious as maintenance treatment. Adapalene has a rapid onset of action and a particularly favorable tolerability profile compared with other retinoids. These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15554742&dopt=Abstract tretinoin Retin-A Renova



Renova Retin-A
Treatment of photodamaged skin with topical tretinoin: an update.

Leyden JJ.

University of Pennsylvania Health System, Philadelphia 19104-4283, USA.

The utility of topical tretinoin in combination with sun protection has now been formally established as a useful approach to the treatment of sun-damaged skin. The early observations of our group have been confirmed in numerous well controlled clinical trials. Moreover, a great deal is known about structural and even molecular changes induced by topical tretinoin, which account for the clinical benefits achieved by this agent. A great deal has been learned in a very short period of time, and these findings represent another major use of retinoid therapy in dermatologic disease.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9774029&dopt=Abstract tretinoin Retin-A Renova



Renova Retin-A
Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety.

Nulman I, Berkovitch M, Klein J, Pastuszak A, Lester RS, Shear N, Koren G.

Department of Pediatrics and Research Institute, The Hospital for Sick Children, Toronto, The University of Toronto, Ontario, Canada.

Isotretinoin is the most potent human teratogen on the market. Women for whom contraception fails may conceive during or soon after discontinuing isotretinoin therapy, making its elimination kinetics a crucial determinant of fetal safety. The steady-state pharmacokinetics of isotretinoin and its major 4-oxo metabolite were studied in 16 adult patients treated for acne who were receiving doses that ranged from 0.47 to 1.7 mg/kg daily. This is the first study of the pharmacokinetics of isotretinoin in women of childbearing age (n = 11). The clinical efficacy and tolerability of isotretinoin was investigated, and the correlation between these data and steady-state serum concentrations of isotretinoin was tested. The concentration-time data best fitted a two-compartment open model with linear elimination. There was no correlation between efficacy and tolerability of isotretinoin and steady-state serum concentrations. There was no correlation between dose of isotretinoin and steady-state concentration, due to the large variability in apparent clearance. Values for elimination half-life (t1/2) of isotretinoin and its metabolite were 29+/-40 hours and 22+/-10 hours, respectively. These data suggest a longer elimination t1/2 of the parent drug than previously reported. This is probably due to the longer sampling time used in this study (as long as 28 days). This study suggests that a greater variability exists in the safe time after discontinuation of the drug for onset of conception.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9807973&dopt=Abstract tretinoin Retin-A Renova



Renova Retin-A
Allergic contact dermatitis to preservatives in topical medicaments.

Skinner SL, Marks JG.

Section of Dermatology, Penn State Geisinger Health System, Penn State University College of Medicine, Hershey, PA, USA.

BACKGROUND: Formaldehyde-releasing preservatives are well-known allergens found in many topical preparations including medications. Objective: To analyze the relevance of a positive patch test to formaldehyde-releasing preservatives in medications containing these preservatives. METHODS: Patients were recruited with a history of allergy to one of these preservatives. Patch and use testing to the medications, vehicles, and preservatives were performed. The following medications and their respective preservatives were used: Renova 0.05% cream/quaternium-15, Dovonex 0.005% cream/diazolidinyl urea, and Temovate-E 0.05% cream/diazolidinyl urea. RESULTS: Nine patients participated in the study. A positive patch test to the preservative was reproduced in six of nine patients, and a questionable reaction occurred in one. Two patients had a positive patch test to the topical medication and one a questionable reaction. There were no definitive positive patch tests to the vehicle but two questionable ones. Use testing revealed three positive reactions to Renova, one to Renova vehicle, and one to Temovate-E vehicle. CONCLUSIONS: The concentration of the preservative in the commercial preparation was often below the threshold necessary to produce a clinical reaction. Use testing is a valuable tool in the complete evaluation of the patient with a positive patch test to a formaldehyde-releasing perservative found in topical medication.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9810018&dopt=Abstract tretinoin Retin-A Renova